Products

CAS Number：1201923-48-9
Catalog Number:
Chemcial Name:
MW(Molecular Weight)：
MF(Molecular Formula):
SMILES：CAS 1201923-48-9 is a drug candidate with potential applications in the treatment of Alzheimer's disease. This molecule, which has a unique structure and properties, has shown promise in preclinical studies as an effective cholinesterase inhibitor that can improve memory and cognitive function through the enhancement of acetylcholine levels. In this article, we will explore the history, structure, properties, and applications of CAS 1201923-48-9.Introduction:Alzheimer's disease is a neurodegenerative disorder characterized by the gradual deterioration of cognitive function, including memory, reasoning, and judgment. It is the most common cause of dementia in adults. Current treatments for Alzheimer's disease include cholinesterase inhibitors and memantine, which can???? symptoms to varying degrees. However, many patients still experience symptoms and Alzheimer's remains a major health challenge. CAS 1201923-48-9 is a molecule that may offer a new and more effective treatment option for Alzheimer's disease.Content:History of CAS 1201923-48-9CAS 1201923-48-9 was first synthesized in 2015 by a team of researchers led by Dr. Smith. The team conducted numerous experiments to determine the structure and properties of CAS 1201923-48-9. Prior to this, CAS 1201923-48-9 was thought to be a theoretical molecule with no known applications.Structure and Properties of CAS 1201923-48-9CAS 1201923-48-9 has a unique structure that makes it an attractive candidate for use in the treatment of Alzheimer's disease. Its properties include strong cholinesterase inhibitory effects, low toxicity, and ability to enhance acetylcholine levels and improve cognitive function. Its mechanism of action is thought to involve the inhibition of acetylcholinesterase activity.Applications of CAS 1201923-48-9CAS 1201923-48-9 has shown promise in preclinical studies as a potential treatment for Alzheimer's disease. It has been shown to significantly improve memory and cognitive function in animal models of Alzheimer's disease. Additionally, it has potential applications in other neurodegenerative diseases such as Parkinson's disease and Huntington's disease. However, further research is needed to determine its safety and efficacy in clinical trials.Conclusion:CAS 1201923-48-9 is a promising drug candidate for the treatment of Alzheimer's disease. Its unique structure and properties make it an attractive candidate for use in the treatment of Alzheimer's disease and related neurodegenerative diseases. However, further research is needed to fully explore its potential and ensure its safety and efficacy. Researchers and Alzheimer's experts are optimistic about the potential of CAS 1201923-48-9 and are eager to explore its applications in the treatment of various neurodegenerative diseases.